1
Cheuk K Lau, Cameron Black, Michel Belley: N-benzyl-3-indoleacetic acids as antiinflammatory drugs. Merck Frosst Canada, Curtis C Panzer, David L Rose, April 23, 1996: US05510368 (143 worldwide citation)

The invention encompasses the novel compound of Formula I as well as a method of treating inflammation and, in particular, cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. # ...


2
Michel Belley, Marc Labelle, Nicholas Lachance, Michel Gallant, Nathalie Chauret, Laird A Trimble, Chun Li: Prostaglandin receptor ligands. Merck Frosst Canada & Co, Raynard Yuro, David L Rose, April 3, 2001: US06211197 (31 worldwide citation)

Compounds and methods for treating prostaglandin mediated diseases, and certain pharmaceutical compositions thereof are disclosed. The compounds are represented by formula II:


3
Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk Kun Lau, Patrick Roy: (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors. Merck Frosst Canada, Richard C Billups, David L Rose, February 1, 2000: US06020343 (25 worldwide citation)

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.


4

5
Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk Kun Lau, Patrick Roy: (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors. Merck Frosst Canada, Richard C Billups, David L Rose, November 9, 1999: US05981576 (6 worldwide citation)

The invention encompasses the novel compound of Formula A that is useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula A.


6
Marc LaBell, Yves LeBlanc, Michel Belley, Erich L Grimm, Daniel Guay, Yi B Xiang: Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists. Merck Frosst Canada, Mollie M Yang, David L Rose, August 1, 1995: US05438141 (3 worldwide citation)

Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, u ...


7

8
Mark LaBelle, Yibin Xiang, Claude Dufresne, Michel Belley: Aza-5,5-fused hetrocyclic acids as leukotriene antagonists. Merck Frosst Canada, Robert J North, Melvin Winokur, September 27, 1994: US05350760 (2 worldwide citation)

Compounds having the formula I: ##STR1## are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, u ...


9
Michel Belley, Jason Burch, John Colucci, Julie Farand, Mario Girard, Yongxin Han: Quinoline derivatives as EP4 antagonists. Merck Canada, Maria V Marucci, Valerie J Camara, September 6, 2011: US08013159 (1 worldwide citation)

The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I ...


10
John Colucci, Marie Claire Wilson, Yongxin Han, Claude Dufresne, Michel Belley, Cheuk K Lau, Christopher Bayly: Fused aromatic PTP-1B inhibitors. Kaneq Pharma, Philippe D Durette, May 1, 2012: US08168815 (1 worldwide citation)

The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated dis ...